Immunotherapy with pembrolizumab deemed cost-effective for advanced melanoma in Hong Kong
EurekAlert (press release) “This is the first study to address the cost-effectiveness of checkpoint inhibitors in the management of advanced cancer in Hong Kong,” said lead author Dr Herbert Loong, Clinical Assistant Professor in the Department of Clinical Oncology of The … |
From:: Hong Kong News By Google News